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Abstract: Familial Mediterranean fever (FMF) (OMIM #249100) is the most common hereditary autoinflammatory disease in the
world. FMF is caused by gain of function mutations of MEFV gene which encodes an immune regulatory protein, pyrin. Over the last
few years, we have witnessed several new developments in the pathogenesis, genetic testing, diagnosis, comorbidities, disease related
damage and treatment approaches to FMF. Elucidation of some of the pathogenic mechanisms has led to the discovery of pathways
involved in inflammatory, metabolic, cardiovascular and degenerative diseases. The use of next generation sequencing in FMF has
revealed many new gene variants whose clinical significance may be clarified by developing functional assays and biomarkers. Clinically,
although FMF is considered an episodic disease characterized by brief attacks, recent systematic studies have defined several associated
chronic inflammatory conditions. Colchicine is the mainstay of FMF treatment, and interleukin (IL)-1 antagonists are the treatment
of choice in refractory or intolerant cases. Experience of IL-1 antagonists, anakinra and canakinumab, is now available in thousands of
colchicine resistant or intolerant FMF patients. In this contemporary review, we surveyed current FMF knowledge in the light of these
recent advances.
Key words: Familial Mediterranean fever, genetics, pathogenesis, diagnosis, clinical features, treatment, prognosis

1. Introduction
Familial Mediterranean fever (FMF) is the most common
hereditary autoinflammatory disease in the world.
It primarily affects populations originated from East
Mediterranean territory though patients are reported
worldwide. FMF is caused by gain of function mutations
in the MEFV gene, which encodes a protein called pyrin
which has regulatory functions on the innate immune
system. For many years the high carrier frequency for
MEFV mutations in Middle Eastern populations was
thought to confer a selective advantage for an unknown
human threat and recent data suggests that it includes the
cause of the “black death”, Yersinia pestis [1].
FMF is characterized mainly by recurrent short-lived
episodes of peritonitis, pleuritis, arthritis, rash, and usually
with accompanying fever. Recent systematic studies have
defined a variety associated inflammatory conditions
in the setting of FMF. As genetic testing has become
cheaper and widely available it is increasingly used in daily
clinical practice. Next generation sequencing (NGS) has
identified many new variants but their clinical associations
are largely unknown, hampering their interpretation.
Functional assays and biomarkers that may aid in
diagnosis, assessment of disease severity and treatment are

under development [2]. Practical indices quantifying FMF
disease severity, activity and recently damage accrual have
been developed and validated for clinical use and research
purposes [3–5].
Colchicine is the mainstay of FMF treatment,
interleukin (IL)-1 antagonists are the treatment of choice
in refractory or intolerant cases and new treatment options
are under development. The use of IL-1 antagonists,
anakinra and canakinumab, has now reached thousands
of colchicine resistant or intolerant FMF patients and data
on their efficacy and safety are becoming more robust.
However, information on their long-term utility in terms
of preventing damage and practice guidelines for the
rational use are still lacking.
It is noteworthy that elucidation of some of the
mechanisms underlying FMF pathogenesis has led to
the discovery of critical immune pathways including
intracellular danger sensors, inflammasomes, pyroptosis
and NETosis, thereby transforming the understanding of
mechanisms and treatment of prevalent inflammatory,
metabolic, cardiovascular and degenerative diseases.
Studies investigating efficacy of colchicine and IL-1
antagonists on these diseases are promising and expanding
[6]. Over the last few years, we have witnessed several
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new developments in FMF pathogenesis, genetic testing,
comorbidities and their management, disease related
damage and treatment approaches. In this contemporary
review, we presented the current knowledge on FMF in the
light of recent advances.
2. Literature search strategy
We conducted a literature search on FMF from 1967
to May 2020 using the Medline, Embase, and Cochrane
databases and the following terms: ‘pathogenesis’, ‘genetics’,
‘manifestation’, ‘chronic inflammation’, ‘treatment’,
‘complication’, ‘amyloidosis’, ‘prognosis’, and ‘familial
Mediterranean fever’. We reviewed abstract archives of
the International Society of Systemic Auto-Inflammatory
Diseases (ISSAID), European League Against Rheumatism
(EULAR), and American College of Rheumatology (ACR)
congresses for unpublished data on specific topics of
interests such as colchicine resistance and intolerance. All
the articles we surveyed were included in Endnote library,
and duplicate articles were removed from the library. We
limited our search to articles published in the English
language.
3. Genetics and pathogenesis
Unusually for a disease largely inherited in an autosomal
recessive fashion, FMF results from gain of function
mutations of Mediterranean fever gene (MEFV), located
on chromosome 16 (16p13.3) [7]. MEFV encodes for a
781 amino acid protein, pyrin (‘pyrin’ or ‘marenostrin’,
TRIM20) which exist in several isoforms both in
cytoplasm and nucleus [8]. The exact function of pyrin
in nucleus is largely unknown. Pyrin has at least four
functional domains; PYD, bBOX, CC and B30.2/SPRY.
Upon activation, pyrin oligomerizes with other cellular
proteins, forming a macromolecular complex called ‘pyrin
inflammasome’ that activates caspase-1 which, in turn,
mediates the release of pro-inflammatory IL-1β and IL18 from their inactive precursors and pyroptosis via the
gasdermin D pathway [1, 9].
Cytoplasmic pyrin interacts with microtubules
in cell skeleton and is a member of cytosolic pattern
recognition receptors (PRRs) which are responsible
for the initiation of rapid innate immune responses by
sensing endogenous danger- or exogenous pathogenassociated molecular patterns (DAMPs and PAMPs).
However, unlike other receptors, pyrin does not recognize
DAMPs/PAMPs directly, but rather detects alterations
in cytoplasmic homeostasis, incited by harmful stimuli,
termed “homeostasis-altering molecular processes”
(HAMPs). These modify RhoA GTPase within cells [10].
In physiologic conditions, RhoA GTPase activates the

serine-threonine kinases; PKN1 and PKN2, that bind
and phosphorylate pyrin. Phosphorylated pyrin binds to
inhibitory 14-3-3 proteins and this process retains pyrin
in an inactive state that prevents formation of the pyrin
inflammasome. In FMF, mutations in MEFV gene impair
interaction of pyrin with microtubules, PKN and 14-3-3
proteins facilitating formation of a proinflammatory pyrin
inflammasome. When the pyrin inflammasome assembled,
it activates caspase-1 to process pro-IL-1β and pro-IL-18 to
their mature forms IL-1β and IL-18, respectively, and cells
undergo an inflammatory death termed pyroptosis. Over
activation of the pyrin inflammasome, and the resulting
inflammation drives typical febrile inflammatory attacks
observed in FMF [10,11].
IL-1β stimulates expression of genes involved in the
entire IL-1 pathway, thereby enhancing its own production,
contributing to an inflammatory burst [12]. Expression of
pyrin can be upregulated by various cytokines: interferon
(IFN)-γ, Tumor Necrosis Factor (TNF)-α, IL-4, and IL10 as well as Lipopolysaccharides (LPS) [10]. Pyrin is
mainly expressed in innate cells – including granulocytes,
cytokine-activated monocytes, dendritic cells, and synovial
as well as serosal fibroblasts – which explains the typical
organ sites involved in FMF1. Although episodic nature
of FMF is not completely understood, during attacks
neutrophil extracellular traps (NETs), i.e. chromatin
ﬁlaments ‘decorated’ with neutrophilic proteins and
captured IL-1β, are formed, restricting further generation
of IL-1β by a negative feedback mechanism, which may
explain the self-limited nature of FMF attacks [13].
MEFV gene has 10 exons and there are more than 370
variants identified to date. The number of variants are
increasing with use of genome sequencing2. Most of the
pathogenic/likely pathogenic variants are located on exon
10 which encodes B30.2/SPRY domain, responsible for the
activation of caspase-1. The most common MEFV variant
is M694V (c.2080A>G) in FMF endemic areas. Other
frequent exon 10 variants are M694I (c.2082G>A), V726A
(c.2177T>C) and M680I (c.2040G>C and c.2040G>A) and
these variants constitute almost 75% of all FMF patients
(Table 1) [14,15]. Carriage of these variants is associated
with the typical clinical phenotype of FMF and with more
severe disease [16]. Benign and likely benign variants are
usually located on exon 2 and generally do not cause typical
phenotype of FMF. Up to two thirds of registered variants
distributed over the entire gene are either not classified or
classified as variant of uncertain significance (VUS) due to
their unknown clinical association [17].
FMF is inherited as autosomal recessive pattern,
however approximately 30% of patients harbour single
pathogenic variant (monoallelic disease) [18]. In FMF

1

The Human Protein Atlas (2020). MEFV [online]. Website https://www.proteinatlas.org/ENSG00000103313-MEFV/tissue [accessed 00 Month Year].

2

Infevers (2020). MEFV sequence variants [online]. Website https://infevers.umai-montpellier.fr/web/search.php?n=1 [accessed 00 Month Year].
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Table 1. Examples of commonly found MEFV gene variants with respect to their clinical
association1.
Benign

Likely benign

VUS

Likely pathogenic

Pathogenic

D102D

R75Q

E148Q

S208T

M680IG>C

G138G

P115T

P369S

F479L

M680I G>A

R202Q

G304R

H478Y

M680L

M694V

R314R

A317T

G678E

I692DEL

M694I

E474E

A457V

T681I

M694L

V726A

D510D

I591M

I720M

K695R

P588P

V690L

V722M

K695N

S675N

I772V

A744S

R761H

Infevers (2020). MEFV sequence variants [online]. Website https://infevers.umai-montpellier.fr/web/
search.php?n=1 [accessed 30 May 2020].
1

prevalent countries and high rate of consanguineous
marriages accumulation of individuals from consecutive
generations might be perceived as dominant inheritance
which is indeed pseudo-dominant transmission. However,
some of MEFV variants with true dominant inheritance
have also been defined [19,20]. Symptom-free individuals
with one identifiable pathogenic MEFV gene variant are
called ‘asymptomatic carriers’ of the disease, and symptomfree individuals harbouring two pathogenic variants are
defined as ‘phenotype 3’ [21].
4. Epidemiology
FMF is prevalent in populations originating from the
Eastern Mediterranean region – namely, Turks, Jews,
Arabs, and Armenians. However hundreds of patients are
reported from Europe, North America and Japan [22,23],
and this figure is expected to increase due to massive
population movements from endemic areas to these latter
regions over the last two decades. FMF’s prevalence varies
from 1:500 to 1:1,000 in endemic countries [22] with
the highest reported prevalence of 1/395, from central
Anatolia region [24]. Considering disease prevalence and
population size, Turkey has the highest number of FMF
patients in the world followed by Israel and Armenia [22].
5. Clinical picture
FMF is characterized by recurrent short-lived inflammatory
attacks which resolve spontaneously within 1–3 days. The
well-known, canonical manifestations of FMF are fever,
serositis, arthritis and erysipelas like erythema [25].
Additionally, a wide array of clinical presentations – such
as neurologic, thrombotic, and ocular disease – have been
reported in FMF settings and referred to as ‘noncanonical
manifestations’ [26]. Some FMF patients may develop
complications of disease in their follow up and some others
may initially present with them, typical example of the

latter is the presentation with amyloid A (AA) amyloidosis
in the absence of classical symptoms which is termed as
phenotype 2.
FMF attacks usually start from early childhood and
80%–90% of patients become symptomatic before the age
of 20 years [25]. Initial manifestations of the disease after
age 40 are fairly rare, and often characterized by a mild
disease course [27]. FMF patients generally recognize
provoking trigger – such as emotional stress, cold
exposure, menstruation, or travel – before the onset of
symptoms [28,29]. Early or premonitory symptoms such
as loss of appetite, irritability and extremity numbness are
described by almost 50% of patients hours before the onset
of full blown attacks [30]. These prodromal symptoms are
more common in men and before the onset of peritonitis
and arthritis attacks [31]. Many individuals describe a
typical individual recurrent attack pattern, which may
help to differentiate attacks from other conditions, such as
acute appendicitis or cholecystitis.
Frequency of type of FMF manifestations differ
between studies according to the enrolled age group,
geographic region and ethnic population. However,
fever and peritonitis are by far the most common
manifestations, reported in more than 90% of patients in
all age and ethnic groups [16,22]. FMF associated fever
usually starts suddenly, spikes within hours and resolves
spontaneously on the same day. The pattern of fever may
help to differentiate FMF from infectious causes and other
autoinflammatory diseases [32]. Fever may occur alone or
accompany other FMF manifestations. In rare instances,
fever might be the only or initial symptom which could be
handled as fever of unknown origin [33,34].
Peritoneal attacks start localized and spread rapidly
involving the entire abdomen. Peritoneal inflammation
causes a typical ileus picture and patients suffer from
crippling stomach pain. Physical examination reveals
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rigidity of the abdominal muscles, rebound tenderness,
and loss of bowel sounds – an emergency scenario
clinically indistinguishable from the surgical causes of
acute abdomen. Thus, a history of unrevealing abdominal
surgery is common among FMF patients (Figure 1A).
In suspected cases, imaging studies may help to exclude
surgical pathologies. A mild rebound diarrhea may follow
abdominal attacks. Despite their dramatic presentation,
all signs and symptoms of peritonitis completely resolve
without a sequela over 24–72 h, though chronic ascites and
peritoneal adhesions have been reported rarely [35].
Less than 50% of patients experience pleural attacks,
which manifest as sudden-onset, unilateral pleuritis and
may occur either alone or in combination with peritonitis
and fever. Patients describe typical severe pleuritic chest
pain and, upon examination, their breath sounds are
diminished on the affected side of their chest. Chest X-rays
may reveal a small exudate at the costophrenic angle.
Attacks usually resolve completely within one to three days
[36,37].
Pericarditis is a rare condition observed in 1%–2% of
patients [38]. Pericarditis gives symptoms as retrosternal
chest pain and dyspnea. Cardiac tamponade may occur
very infrequently. An electrocardiogram shows an
elevated ST segment, chest X-rays may reveal transient
enlargement of the cardiac silhouette (Figures 1B and 1C),
and echocardiography shows accumulation of pericardial
fluid [39]. Rarely, recurrent pericarditis can be the sole
manifestation of FMF, which might be confused with
idiopathic pericarditis [40,41].
Arthritis is the third most common manifestation
of FMF affecting more than 50% of patients. Articular
attacks occur as sudden-onset, painful, swollen joints.
These attacks involve one or two large joints of the lower
extremities and can be accompanied by fever, a condition
indistinguishable from septic arthritis (Figures 2A and
2B). Joint aspirate reveals a sterile inflammatory effusion
(Figure 2C). Symptoms peak in one to three days and
subside spontaneously within a week. Protracted arthritis
is observed in fewer than 5% of patients, and permanent
damage may occur in a small proportion of patients –
particularly when the hip joints are involved (Figure 3).
Chronic sacroiliitis is reported in approximately 10% of
FMF patients [42]. Articular attacks are more common
in patients harbouring an M694V mutation, and it is
associated with more severe disease as well as increased
risk of AA amyloidosis [43].
Muscular complaints are common in FMF patients,
particularly those carrying the M694V mutation. The
most common muscular symptom is standing myalgia
(exertional leg pain) which occurs in calf muscles. Attacks
might be evoked by long travel and probably by passive
vibration. Myalgia is associated with more severe disease
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and persistent inflammation [44,45] that can be easily
overlooked if not meticulously questioned. The most
severe muscular presentation is protracted febrile myalgia
(PFM) which is characterized by intense myalgia and fever
with prolonged complaints up to 10 weeks. PFM causes
a marked acute-phase response, and magnetic resonance
imaging reveals muscle oedema (Figure 4). The condition
is refractory to colchicine and may even occur despite
regular colchicine use [46].
The skin manifestations of FMF present as a patchy
skin rash resembling typical erysipelas (erysipelas-like
erythema, ELE) or as painful purpura resulting from
leukocytoclastic vasculitis (Figure 5). Skin attacks usually
follow long travel or prolonged walking and occur mostly
on the legs, around the ankle, or on the dorsum of the feet.
A wide array of presentations – including
vasculitic, neurologic, thrombotic, ocular, and cochlear
disorders– have been reported in FMF patients and
defined as ‘non-canonical manifestations’ [26]. However,
the prevalence and pathogenetic associations of them with
FMF have not been well characterized in most of these
disorders, which might also be interpreted as coincidental
occurrences [47].
It has long been noted that FMF patients and
asymptomatic carriers are vulnerable to certain
inflammatory diseases, such as spondyloarthritis, Henoch–
Schönlein purpura (HSP), and polyarteritis nodosa (PAN)
[48]. The increased incidence of these particular diseases in
FMF patients can be explained by an enhanced expression
of proinflammatory cytokines and microRNAs. Recent
publications have expanded this list to include: juvenile
idiopathic arthritis, PFAPA, spondyloarthropathies,
inflammatory bowel disease, vasculitides (Behçet’s
disease, HSP, PAN), glomerulonephritis, skin diseases
(psoriasis, hidradenitis suppurativa, contact dermatitis),
and demyelinating brain disease [48–52]. Most of these
comorbid conditions fall under MHC Class I group
diseases (MHC-I-opathies), whereas MHC-II–spectrum
(autoimmune) diseases have a comparable prevalence
among the general population [48,49].
Phenotype 2 FMF is characterized by initial
presentation with AA amyloidosis in the absence of other
classical manifestations of FMF disease. This phenotype
constitutes fewer than 2% of patients in different cohorts
[38]. Diagnosis requires genetic analysis and exclusion of
other causes of chronic inflammation.
Although FMF is characterized by intermittent
inflammatory attacks, a substantial number of patients
have chronic, ongoing inflammation. In a prospective
study, only 29% of serum amyloid A (SAA) measurements
in FMF patients were less than 3 mg/L, 65% were less than
10 mg/L, and 13% exceeded 50 mg/L [53]. Independent risk
factors for chronic inflammation were male sex, M694V
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Figure 1. (A) A patient with scars from multiple abdominal surgeries, (B) chest X-ray showing massive pericardial effusion, (C)
chest X-ray of the same patient after treatment with anakinra.

Figure 2. (A) A patient with acute knee arthritis, (B) chronic deforming arthritis involving both knees, (C) joint aspirate
showing sterile inflammatory effusion.

homozygosity, musculoskeletal-type attacks, colchicine
resistance, and inflammatory comorbidities [54]. Chronic
inflammation constitutes a major risk for the development
of amyloidosis, kidney failure and other complications of
disease [54,55].
6. Genetics and environmental factors’ effects on
phenotypic variation
The heterogeneous disease course of FMF results from
a complex interplay between genetic and environmental
factors. The final disease phenotype primarily determined

by the MEFV variants carried [14]. M694V is the most
common and the most penetrant variant causing more
pronounced caspase-1, IL-1 family cytokine and S100A12
secretion from neutrophils [56].
Patients harbouring biallelic exon 10 variants –
particularly variants which are homozygous for M694V
– exhibit a severe disease phenotype characterized by an
earlier age of onset, more frequent attacks, musculoskeletal
features, lower colchicine response, chronic inflammation,
increased risk of comorbid conditions, and disease
complications including infertility, joint damage, and
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Figure 3. (A) Acute right hip joint arthritis, (B) permanent destruction in the same joint in the long term.

Figure 4. (A) Coronal and (B) axial T2-weighted fat saturation magnetic resonance images of the right calf muscles showing
increased intensity and severe swelling due to muscular inflammation.

secondary amyloidosis [38, 57–59]. Disease associated
with a single mutation (MEFV heterozygotes) typically is
milder than in individuals with homozygous or compound
heterozygous pathogenic variants, characterized by
later onset, less frequent fever/serositis type attacks,
more favorable response to colchicine and lower risk of
disease complications [60,61]. However this is not always
the case and reports exist of more severe single variant
disease which might be due to inclusion of high number
of patients carrying single heterozygous M694V mutation
[62]. Approximately 10%–20% of FMF patients in different
cohorts do not carry any identified MEFV mutation though
it is contentious whether this condition is FMF-like disease
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or true FMF with as yet unidentified genetic variations
[14]. Nevertheless, after extensive genetic testing there are
a number of confirmed mutation negative patients who
show a mild disease phenotype similar to those with single
heterozygous subjects [63].
The symptoms and severity of FMF can vary among
affected individuals with the same MEFV variant, even among
members of the same family [64] suggesting contributions by
a number of modifiers – including other genes, epigenetic
and environmental factors. Based on twin studies relative
contribution of MEFV, non-MEFV genetic factors and
environmental factors on phenotypic variation are estimated
at a ratio of 6:1.5:1, respectively [65]. The known MEFV

TUFAN and LACHMANN / Turk J Med Sci

Figure 5. Skin manifestations of familial Mediterranean fever. (A) Erysipelas like erythema (ELE) on the dorsum of the foot, and
(B) painful purpura.

independent genetic modifiers are polymorphisms of IL-1β
which is associated with disease severity [66] and harboring
alpha/alpha genotype for serum amyloid A protein 1 (SAA1)
gene which increases the risk of developing AA amyloidosis
without affecting FMF disease characteristics [67]. Although
specific alterations have been reported in epigenetics such
as microRNAs and DNA methylation, their contribution
to phenotypic variation has yet to be clarified [68–70].
The influence of specific environmental factors on FMF
phenotype have not been defined, but country of residence is
repeatedly reported as an independent modifier with living
in Turkey, Armenia and Middle East increasing risk of severe
disease and AA amyloidosis [71–74].
7. Diagnosis
The diagnosis of FMF is made based on the patient history,
inflammatory markers and more recently by genetic testing.
Several clinical diagnostic criteria sets have been proposed
for the diagnosis of FMF. The Tel Hashomer criteria,
Livneh criteria and Turkish pediatric criteria all rely on the
clinical symptoms, family history and colchicine response.
The oldest and maybe the most widely used criteria set
is the Tel Hashomer, which includes fever, peritonitis,
pleuritis, arthritis, ELE, amyloidosis and family history
[25]. In 1997, Livneh et al. created a new set derived from
the Tel Hashomer criteria but including exertional leg
pain and laboratory findings (inflammatory markers and
urinary findings, proteinuria/hematuria) and excluding
amyloidosis. Both extended and simplified versions of
Livneh criteria have a reported sensitivity and specificity
of >95% [75]. In 2009, Turkish paediatric criteria for FMF
were developed with the inclusion of family history and
clinical characteristics of fever, arthritis, stomach, and
chest pain. Children with two or more of these criteria can
be diagnosed with FMF with a reported sensitivity and
specificity of 86.5% and 93.6%, respectively [76].

Clinical criteria are supposed to be sufficient for the
diagnosis of FMF in endemic countries [22]. However,
diagnosis of FMF can be difficult and delayed with use
of clinical criteria, if the physician experience of FMF
symptoms is limited and when the patient has hazy or
atypical symptoms. After molecular cloning of MEFV,
genetic testing become available as a diagnostic adjunct,
especially in atypical cases and phenotype 2 patients.
Recently, Eurofever/PRINTO group released classification
(not diagnostic) criteria combining genetic test results and
the following clinical features; attacks lasting 1–3 days,
arthritis, abdominal and chest pain [77]. According to
Eurofever/PRINTO, individuals with biallelic pathogenic/
likely pathogenic variants and one clinical feature are
classified as FMF, whereas patients harbouring one
pathogenic or likely pathogenic variant or low penetrant
biallelic variants are required to have two or more clinical
features in order to be classified as having FMF. The
performance of three clinical FMF diagnostic criteria and
the new Eurofever/PRINTO classification criteria was
recently tested in a real-life setting on paediatric patients.
All of the criteria sets revealed similar performance in
diagnosing or classifying patients with biallelic pathogenic
variants, but the Eurofever/PRINTO classification criteria
had a somewhat lower sensitivity for patients with
monoallelic variants (heterozygotes) [78,79].
Genetic testing is recommended in suspicion of FMF in
non-endemic countries to support/confirm diagnosis but
also give valuable information about the severity of disease,
like colchicine response, risk of disease complications and
ultimately long-term prognosis [80,81]. Genetic testing
can be performed either by Sanger or single gene NGS.
ISSAID/European Molecular Genetics Quality Network
(EMQN) recommends a limited initial MEFV exon 10
sequencing in patients with suspected of FMF [82]. NGS
might reveal many clinically undetermined variants
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complicating interpretation of test results. A recently
reported consensus-driven pathogenicity classification
failed to classify almost half of the MEFV variants (42.4%)
[83]. Functional assays may ascertain pathogenicity of
such variants but these are in their infancy and have not
been performed for many of them [81]. Lamkanfi et al.
recently developed a functional diagnostic test for FMF,
ex vivo colchicine assay, with a sensitivity of 86% and
specificity of 100%. The test was based on colchicine’s in
vitro inhibitory effect on peripheral blood mononuclear
cells for the secretion of IL-1β and IL-18 via stimulation
with Clostridium difficile toxin A [2].
Commonly used markers of inflammation leukocyte
count, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), serum amyloid A protein (SAA) and
fibrinogen are increased during attacks and should return
to their normal values in between attacks. CRP, SAA and
fibrinogen are produced from liver upon stimulation with
proinflammatory cytokines including IL-1β, IL-6, TNF-α
and IFN-γ. SAA is found in trace amounts in plasma (normal
range <3 mg/L) and its concentration can rapidly increase
up to 1000-fold within 24 h in response to inflammatory
stimuli [84]. SAA is the precursor of AA amyloid fibrils
and sustained long-term elevation of SAA concentration
is the only known prerequisite for the development of
AA amyloidosis [53]. Similarly, CRP values can rise
dramatically up to hundred-folds after an inflammatory
stimulus. In a prospective study, Lachmann et al. showed
that both SAA and hs-CRP were massively elevated during
all reported clinical attacks of FMF in all patients, with
median values of 693 (range of 140–1330) mg/L and 115
(range of 26–296) mg/L, respectively [53]. Hence, SAA
is the most sensitive biomarker and is recommended
to adjust colchicine dose and minimize the risk of AA
amyloidosis. Although acute phase proteins (APRs) are
helpful in corroborating clinical attacks and inflammatory
activity, they all lack specificity for diagnostic use. S100
proteins are DAMP-family molecules which induce IL-1β
release with a positive feedback loop. Massively increased
(100-fold) S100A12 serum concentrations during and
between attacks are suggested to be very specific for FMF

and systemic-onset JIA, which may help diagnose and
monitor inflammatory activity [85].
Indisputably, the most valuable tool in FMF diagnosis
is a proper patient history which should include details
of symptoms, past medical history, ethnicity and family
history. Currently, MEFV molecular genetic testing is
readily available, but test results are not unequivocal, and
they need to be evaluated cautiously in the clinical context.
If both clinical assessment and the genetic testing are
inconclusive and the condition is not better explained by
an alternative diagnosis, a therapeutic trial of colchicine
is given for 3–6 months to ascertain treatment response.
However, it should be noted that the diagnostic sensitivity
of this approach is almost 90% but its specificity is as low
as 15%, resulting in a high rate of false positive diagnoses
[86]. Therefore, under this approach, patients should
be monitored for the onset of new symptoms that direct
alternative diagnoses while maintaining colchicine.
8. Differential diagnosis of FMF
Several diseases may mimic the symptoms of FMF, and
they should be considered during diagnosis and in the case
of colchicine nonresponse (Table 2).
9. Treatment
The goals of treatment in FMF are improving quality of
life (QoL), reducing frequency, severity and duration of
attacks and prevention of long term damage, particularly
AA amyloidosis by minimizing chronic/subclinical
inflammation. There is great heterogeneity between
individuals for the type and severity of attacks. Hence,
treatment should be tailored individually with monitoring
attacks and inflammatory markers/proteinuria [87]. FMF
treatment can be divided into three parts:
· Attack and AA amyloidosis prophylaxis,
· Treatment of acute episodes,
· Management of comorbid conditions and
complications.
Prior to 1972 and the seminal observation that
colchicine prophylaxis decreases FMF attacks and
subsequently the risk of AA amyloidosis, more than 50%

Table 2. Differential diagnoses of familial Mediterranean fever.
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Mevalonate kinase deficiency (MKD)

Inflammatory bowel disease

TNF receptor-associated periodic syndrome (TRAPS)

Porphyria

Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy (PFAPA)

Median arcuate ligament syndrome

Hereditary angioedema

Intestinal adhesion

Fabry disease

Adrenal failure

Cyclic neutropenia

Chronic recurrent infections

Yao syndrome

Mesothelioma
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of patients with FMF died of amyloidosis [25,88]. But
even recently AA amyloidosis is a major problem among
FMF patients affecting up to 10% of patients in large series
[89]. Four randomized controlled trials (RCTs) [90–93]
and decades of experience concretize colchicine’s safety
and efficacy in FMF treatment. The risk of amyloidosis in
patients who adhere to colchicine therapy is less than 1% in
the long term – even in the absence of a complete control
of attacks [88]. Therefore, lifetime colchicine prophylaxis
is recommended in all FMF patients, regardless of
symptoms, unless a severe side effect ensues.
Colchicine is an ancient agent used for centuries for
the treatment of gout. Although its precise mechanism of
action is unknown, colchicine has inhibitory functions
on microtubule polymerization, adhesion molecules,
neutrophil chemotaxis, and NLRP3 inflammasome [94].
It is thought to exert these effects primarily on neutrophils
due to selected accumulation in these cells as they lack
the P glycoprotein efflux pump [95]. Colchicine’s bioavailability ranges from 24% to 88% while its elimination
half-life ranges from 20 to 40 h and is prolonged in
patients with liver and kidney impairment [94]. It has a
narrow therapeutic index while being clinically effective
in most FMF patients at blood concentrations <7 ng/mL,
but it can cause serious toxicities, multiple organ failure,
and death at concentrations >10 ng/mL [96]. Oral doses of
1–1.5 mg/day is the optimal dose in most patients for the
prevention of attacks and AA amyloidosis [22,97]. But the
dosage can be increased to a maximum of 2.5–3 mg/day if
the response is inadequate [97–99]. In previous long-term
studies with large number of pediatric and adult patients,
titrating the dose to control symptoms resulted in less than
1% risk of proteinuria [98]. However, it’s prudent to keep
dosage ≥1.5 mg/day in patients with or at high risk of AA
amyloidosis, provided that the liver and kidney functions
are normal [100]. The dose can be taken once or divided
according to gastrointestinal tolerance. Colchicine is safe
and even improves pregnancy outcome, so it must be
continued during pregnancy and while breastfeeding [96,
98]
The foremost side effects of colchicine are diarrhoea,
elevation in transaminases, leukopenia, and neuromuscular
toxicity – which all require regular monitoring. Colchicine
strongly interacts with tubulin, cytochrome P3A4
(CYP3A4), and P-glycoprotein. Therefore, the risk of
toxicity increases when colchicine is combined with
drugs or foods which are substrates of these proteins.
Many fatalities have been reported with the combined
use of clarithromycin, cyclosporin, lipid-lowering drugs,
and grapefruit [94]. Howbeit, colchicine is generally safe,
requiring permanent cessation in 2% of patients in long
term [101]. Nonetheless, colchicine intolerance constitutes
a major problem, with almost one-fifth of patients unable to

maintain optimal doses [101]. In a large cohort, diarrhoea
(10.8%), transaminitis (5.9%), leukopenia (1.1%), renal
impairment (1.3%), myopathy (0.5%), and occasional skin
side effects hindered optimal colchicine dosing [101]. Of
note colchicine frequently unmasks lactose intolerance and
GI side effects can often be ameliorated by introduction of
a lactose free diet, particularly in those with a high milk or
other dairy product intake.
Ultimately, colchicine at doses of 1–2 mg/day, titrated
according to response, has provided 64% complete and
31% partial response in the long term [102]. However,
about 5%–10% of patients do not respond well to
colchicine, requiring additional treatment [102]. Patients
with M694V homozygous or biallelic exon 10 variants,
severe disease, or musculoskeletal and skin manifestations
are more likely to be colchicine-nonresponsive, whereas
patients with serositis or fever-type attacks and singleheterozygous variants may respond to lower colchicine
doses [103]. Colchicine cessation can be possible in the
latter group provided that they are in complete remission
for at least for 3–5 years, has normal acute phase levels, at
low risk of AA amyloidosis and adhere with regular follow
up [104,105]. However, most physicians prefer lifelong
colchicine prophylaxis. Nevertheless, colchicine-free longterm remission is possible in minority of patients [104].
9.1. Treatment of colchicine-resistant or -intolerant
patients
No clear consensus offers a precise definition of ‘colchicine
resistance’, but experiencing monthly attacks or persistently
elevated inflammation markers despite the adherence of a
maximally tolerated colchicine is the most widely accepted
definition [99,106]. Colchicine-resistant (crFMF) or
colchicine-intolerant (ciFMF) patients are candidates for
biologic therapies, but guidelines for their use are lacking.
Therefore, before starting biologics, there are several issues
to consider: patients’ quality of life, work productivity
and disposition, the presence of chronic inflammation,
and reimbursement for drug costs. Furthermore, causes
of nonresponse should be carefully reviewed, including
attack mimics, comorbid conditions, potent attack
inducers, malabsorption and, most importantly, treatment
adherence [96,107]. Avoidance of precipitating factors –
such as cold exposure, strenuous exercise, certain drugs,
and certain foods – might reduce the frequency of attacks.
A prospective observation period of three to six months
to confirm attacks and determine inciting factors is
recommended before the use of biologic drugs [108].
Three IL-1 antagonists have been studied in the
treatment of crFMF: anakinra, canakinumab, and
rilonacept. All of the IL-1 antagonists significantly reduce
the number of attacks and improve quality of life with
good safety profiles [108,109]. Good quality studies are
scarce for the use of IL-1 antagonists and all randomized

1599

TUFAN and LACHMANN / Turk J Med Sci
or open label studies included relatively small numbers
of patients. Most of the evidence comes from single case
reports or case series. The most commonly used drugs for
crFMF are anakinra and canakinumab [110]. There are no
comparative studies between agents for canakinumab vs.
anakinra, so both agents can be used for the management
of crFMF and ciFMF patients. Their long-term efficacy and
safety are unknown, but they are effective in stabilizing
and improving FMF complications such as proteinuria
in the short term, suggesting potential benefits in the
long term [111,112]. Hence, until the long-term effects of
IL-1 antagonists are demonstrated, colchicine should be
coadministered unless it is contra-indicated. The rate of
infection is low with use of IL-1 antagonists and the main
limitation for their use is their financial expense.
Anakinra, a recombinant IL-1 receptor antagonist
(rHIL-1Ra), was the first IL-1 blocking biologic agent
produced and inhibits binding of both IL-1α and IL-1β
to the IL-1 receptor. It is the most extensively used IL-1
blocker in FMF treatment and, currently, the cheapest one
[108]. Anakinra was studied in only one RCT included 25
FMF patients (12 in anakinra and 13 in placebo arms). All
12 patients responded, and seven (58.3%) were complete
responders [113]. Anakinra has a relatively short half-life
(4–6 h) requiring daily injections. An advantage of the
short half-life is that it can be used as a diagnostic challenge
test for the suspected IL-1 mediated diseases [114] and
also to determine whether an unusual manifestation
relates to FMF itself [115]. Moreover, anakinra’s short
half-life allows its use in the preattack prodromal period
to alleviate the symptoms of an impending attack. The
prophylactic, intermittent, short-period use of anakinra
before exposure to known predictable triggers, such as
menstruation and travel, might also be effective [116]. The
recommended dose for anakinra is 1–2 mg/kg/day with a
maximum daily dose of 8 mg/kg. The usual treatment dose
is 100 mg/day, and the dose can be escalated according
to patient response – though multiple doses are hardly

tolerated by patients due to painful injections. The mean
plasma clearance of anakinra decreases by 70%–75% in
patients with end-stage renal disease (ESRD), requiring
a dosage adjustment (i.e. starting with a dose of 100 mg
every other day). Other significant side effects are skin
reactions, leukopenia, infections, and weight gain (Figure
6). Loss of efficacy may occur in long-term use, which is an
indication for switching to canakinumab treatment [110].
Canakinumab differs from anakinra in that it
specifically blocks IL-1β. It has a mean plasma half-life of 26
days, allowing for monthly or bimonthly administrations.
Canakinumab is the only licensed drug in Europe and
the United States for the treatment of crFMF. Two openlabel trials and one RCT evaluated canakinumab’s efficacy.
Once-every-four-weeks doses of 150 mg (2 mg/kg in
children) of canakinumab provided a complete response
of 61% in CLUSTER trial, and when the dose doubled
for patients with partial responses (300 mg in adults,
4 mg/kg in children, every four weeks), the complete
response rate increased to 71% [117]. In light of this study,
canakinumab is started at 150 mg/month and, according
to response, the dose can increase to a maximum of 300
mg/month or taper to 150 mg every other month. In daily
practice, canakinumab injections are more comfortable
than anakinra injections, which might improve treatment
compliance [110].
Rilonacept, an IL-1 decoy receptor, binds to IL-1β
and – to a lesser extent – IL-1α. Rilonacept is the leaststudied and least-used IL-1 antagonist in FMF treatment.
In a small RCT comprising 14 patients, two patients had
a complete response while eight had a partial response
and two had no response during a three-month treatment
course [118].
Tocilizumab is a humanized monoclonal antibody
against the interleukin-6 receptor, and it has potent
suppressive effects in the production of APRs. Although
FMF is considered an IL-1 mediated disease, serum IL-6
concentrations have been found to be elevated in FMF

Figure 6. Side effects of anakinra (A) injection site reaction, (B) lipoatrophy, (C) toxic epidermal necrolysis.
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patients, particularly during attacks [119]. Yilmaz et al.
treated 11 FMF amyloidosis patients with a monthly
infusion of 8 mg/kg of tocilizumab for a duration of three
to 16 months. Proteinuria improved or stabilized in eight
patients, and no attacks were observed in ten patients
[120]. After proteinuria normalization, the researchers
discontinued tocilizumab in two patients, which resulted
in a relapse of proteinuria for both patients [121]. Another
study by Ugurlu et al. observed similar results [122].
Ongoing RCTs in Germany (NCT03446209) and Japan
(UMIN000028010) will explore role of tocilizumab in
treatment of crFMF and ciFMF patients.
9.2. Treatment of acute episodes
The therapeutic approach to an acute FMF episode
is mainly supportive, including the administration of
intravenous saline for hydration and the use of analgesics
[97]. However, it has been suggested that the use of anakinra
in the prodromal period might abrogate or alleviate the
symptoms of an imminent attack [31,116]. Many patients
report antecedent precipitating insults before attacks, and
70% of these insults were followed by an attack [123].
Therefore, use of anakinra soon after a powerful attack
trigger would also be a reasonable approach. Anakinra
can be used in acute attacks which are potentially life
threatening, expected to be last longer or leave permanent
damage, such as pericarditis, febrile myalgia and hip joint
arthritis.
9.3. Treatment of comorbidities
As we mentioned earlier, various inflammatory conditions
may accompany FMF. The treatment of these conditions
is the same when they accompany FMF as their usual
treatment in non-FMF patients. However, some of the

successful reported treatments are disclosed in Table
3. Interestingly, some of the inflammatory comorbid
conditions in the course of FMF may also respond well to
IL-1 inhibitors, such as spondyloarthritis, Behçet’s disease,
inflammatory bowel disease, protracted febrile myalgia,
hidradenitis suppurativa, pustular psoriasis, and HSP
[108].
Chronic arthritis in FMF does not respond to
colchicine alone and requires additional medications, such
as disease-modifying antirheumatic drugs (DMARDs),
intraarticular steroid injections, or biologics (Table
3). Similarly, protracted febrile myalgia is resistant to
colchicine, which can be treated with glucocorticoids,
NSAIDs, and IL-1 antagonists.
9.4. Treatment of complications
Colchicine can stabilize or even improve proteinuria
in FMF-associated amyloidosis in colchicine-naïve or
noncompliant patients with serum creatinine levels of <1.5
mg/dL, and the dose should not be less than 1.5 mg/day for
such patients [100] though dose adjustment is necessary in
the case of reduced creatinine clearance. Intensive blood
pressure control should be maintained in all proteinuric
subjects along with anti-lipidemic treatments. There is a
significant correlation between serum SAA concentration
and increased risk of death from amyloidosis, with ~4-,
~5-, and ~12-folds for values above 4, ~10, and ~45
mg/L, respectively [84]. Therefore, for patients with AA
amyloidosis and ongoing inflammatory activity (preferably
assessed with SAA or CRP) despite the maximum tolerated
dose of colchicine, biologic treatments should be promptly
initiated. The target SAA value would be less than 10
mg/L, since this cut-off has a 60% chance of regression

Table 3. Selected comorbidities and reported successful treatments.
Condition

Chronic arthritis

Sacroiliitis

AA Amyloidosis

PFM

Treatment(s)

Study

Reference

DMARDs

Case series

[143,144]

Anti-IL-1

Case series

[110]

Anti-TNF

Case series

[145,146]

Tofacitinib

Case series

[147]

Anti-TNF

Case series

[146]

Anti-IL-1

Case series

[148]

Anti-IL-1

Case series

[111,112,149,150]

Anti-IL-6

Case series

[120,122, 151–154]

Interferon-α2a

Case

[155]

Anti-TNF

Case series

[156,157]

Anti-IL-1

Case series

[46,158,159]

DMARDs: Disease modifying antirheumatic drugs, IL: Interleukin, PFM: Protracted febrile
myalgia, TNF: Tumor necrosis factor.
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in amyloid deposits and improved survival [84]. If SAA
is not available, CRP values 5 mg/L in FMF children or
8.75 mg/L in FMF adults during attack-free periods can
be a convenient substitute to guide therapeutic decisions
[124]. The use of IL-1 inhibitors improves AA amyloidosis
patients’ renal function [111,112].
End-stage renal disease caused by renal amyloidosis
should be treated the same way as other causes of
renal failure, including transplantation. After kidney
transplantation, tight control of inflammation should
be maintained, and colchicine drug interactions must
be carefully assessed. Tight inflammation control may
also improve complications other than AA amyloidosis,
such as growth retardation and infertility. The use of
IL-1 inhibitors has been shown to restore fertility in FMF
patients suffering from infertility or subfertility [125].
9.5. Approach to patients with chronic subclinical
inflammation
Chronic inflammation constitutes a substantial risk for
AA amyloidosis, growth retardation, and cardiovascular
disease [54]. In such cases, FMF disease activity must be
carefully assessed using prospective patient diaries and
in confirmed quiescent patients, all other possible causes
of chronic inflammation should be ruled out, including
inflammatory comorbidities and chronic infections [55].
In true asymptomatic patients, colchicine dose must
be increased/maintained at maximum tolerated doses
until SAA normalizes which has been demonstrated
previously [98, 126]. Currently, there is no evidence to
support routinely recommending IL-1 or IL-6 antagonists
to patients in clinical remission but with elevated APRs.
However, a vigilant follow-up for proteinuria and promptly
initiating IL-1 or IL-6 antagonists when microalbuminuria
is detected, and use of them in those at high risk of AA
amyloidosis (presence of several risk factors) would be the
reasonable approaches. One issue is that even in patients at
high risk of amyloidosis, acceptance and adherence to IL-1
antagonists in the absence of symptoms is low.

10. Prognosis
FMF has an excellent prognosis if diagnosed and
treated early, before complications develop. Serious
complications almost always develop in colchicineuncompliant or -resistant cases or among patients with
delayed diagnoses. In a recent study, we found in a
large cohort that more than half of FMF patients suffer
from at least one disease complication [127], assessed
by autoinflammatory disease damage index (ADDI)
[5]. Damage mainly occur in the musculoskeletal,
reproductive, and excretory systems – including growth
retardation, pubertal delay, amenorrhea, infertility or
subfertility, proteinuria, AA amyloidosis, kidney failure,
serosal scarring and adhesions, musculoskeletal pain,
joint deformity, and osteoporosis[127]. Risk factors for
damage are M694V homozygosity, colchicine resistance/
nonadherence, musculoskeletal attacks, diagnostic
delay, disease duration and chronic inflammation
[127]. Systemic AA amyloidosis is the leading cause of
morbidity and mortality in FMF [128,129], therefore
patients with defined risk factors should be meticulously
followed (Table 4). After the diagnosis of AA amyloidosis,
end stage renal disease develops in median five years and
the 5-year survival rate was reported as 50% [130,131].
Allograft survival after transplantation is poorer in FMF
associated amyloidosis than other causes of ESRD [132,
133].
Poor sleep quality, anxiety, depression and fatigue
are frequently neglected health issues in FMF patients
[134,135]. Work productivity is impaired in severe disease
and can be improved with good control of disease with
colchicine and IL-1 antagonists. Reports have suggested
that FMF patients have significantly lower incidence of
cancer than the general population [136, 137], raising
speculations that MEFV can act as an oncosuppressor
gene [138]. On the other hand, numerous reported cases
describe mesothelioma in FMF, attributed to chronic
serosal inflammation [138].

Table 4. Risk factors for AA amyloidosis.
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Characteristics

Fold risk increase

Reference

Male sex

1.7– 4

[67,160]

Arthritis

2.3 – 2.4

[127,160,161]

Very frequent attacks ≥20 per year

2.0

[74]

Family history of AA amyloidosis

2.0

[74]

Chronic inflammation

3.59–13

[54,55]

M694V homozygosity

2.6–4.3

[74,160]

SAA1 α/α genotype

3–6.9

[67,160]

Living in Turkey, Middle East, Armenia vs. Europe

1.5–3.2

[74]
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11. Follow-up
After an FMF diagnosis, all of the patient’s family members
should be evaluated for the disease. Colchicine should
be initiated immediately upon a clinical FMF diagnosis.
Response, toxicity, and compliance should be monitored
every three to six months. Persistence of attacks or
subclinical inflammation represents disease activity and an
indication to increase colchicine dosage [99]. Monitoring
disease activity with a diary is probably the best way
to assess the frequency and duration of attacks and to
ascertain precipitating factors. Paper and mobile phone
application versions (AIDD) of patient diaries exist, but
patient adherence is poor. Wearable technology could be
a promising tool to monitor disease activity by capturing
attacks based on abrupt decline in routine physical activity
[139].
Complete blood count, liver enzymes, creatinine, CRP
or SAA, and urinalysis should be monitored every three to
six months to monitor colchicine toxicity, inflammatory
activity, and proteinuria [99]. A kidney biopsy is
recommended whenever the urinary protein excretion
exceeds 0.5 g/24 h to exclude AA amyloidosis [140]. More
convenient sites for the tissue biopsies are abdominal fat and
minor salivary glands [141]. The other option for patients
with suspected amyloidosis is the use of a serum amyloid P
(SAP) scan but it is only available at certain centers [142].

12. Future perspectives
Genetic testing, combined with functional assays, might
be the diagnostic strategy in the near future, and it
may also aid in treatment planning. Extension studies
will disclose the long-term benefits of IL-1 antagonists
in terms of preventing damage. Clinical trials could,
moreover, investigate the efficacy of caspase inhibitors and
more potent colchicine derivatives. Since FMF commonly
results from missense mutations, CRISPR/Cas9 system
could potentially provide a cure in the future.
13. Conclusion
FMF is an enigmatic disease in both its pathogenesis
and clinical manifestations. Although FMF manifests
with intermittent attacks, many patients suffer from
complications of disease. Early diagnosis and adherence
to treatment are key issues for the well-being of patients.
Although the last 25 years has seen major progress
regarding the pathogenesis, diagnosis and treatment of
FMF, there are many questions awaiting their answers
such as episodic nature of disease, variants of unknown
significance, epigenetics and rational use of biologic drugs.
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